The National Guideline for Cervical Cancer Screening

Objectives

The United Arab Emirates National Cervical Cancer Screening Programme sets clinical service specifications, a standardised care pathway and minimum quality requirements for safe, accessible and quality-assured cervical cancer screening, follow-up, referral, diagnosis and treatment. It applies to licensed healthcare facilities and professionals providing screening in the United Arab Emirates.[1]The programme targets sexually active, symptom-free women aged 25 to 65 years who reside in the United Arab Emirates and meet eligibility criteria.[2]

• Provide risk assessment, physical examination, cervical-smear collection, specimen handling, cytology reporting, follow-up and referral within the provider’s licensed scope of practice.[1]
• Use the Papanicolaou test as the standard screening test, collect specimens through liquid-based cytology, and offer internationally approved human papillomavirus co-testing to women aged 30 years and above.[2]
• Screen average-risk women aged 25 to 29 every three years and those aged 30 to 65 every five years, while providing annual screening for women immunocompromised through disease or medication.[2]
• Exclude women with a total hysterectomy for benign indications and women over 65 whose previous two cervical smears were negative, while continuing screening after subtotal hysterectomy or hysterectomy for cervical cancer or precancer.[2]
• Maintain screening recommendations irrespective of human papillomavirus vaccination status.[2]
• Match facility capacity and appointment allocation to screening demand, maintain suitable equipment, and protect privacy, comfort and confidentiality.[3]
• Ensure cytology processing is undertaken by licensed laboratories meeting applicable standards and screening is delivered by appropriately licensed and trained personnel.[3]

Implementation

Implementation is delivered through registered licensed screening facilities, laboratories, healthcare professionals, diagnostic and treatment centres, coordinated with the Ministry of Health and Prevention, the National Cancer Screening Programme, the National Cervical Cancer Screening Task Force and cancer-control teams.[1][4][3]Each participating facility requires a coordinator to recruit eligible women, track results and follow-up, support protocol compliance, address barriers, operate recall systems, and submit screening-visit and outcome data through the electronic notification system to the Ministry of Health and Prevention.[4][5]

• Register facilities through communication with the cancer-control team, service-provision documentation, participation confirmation, orientation and reporting credentials before screening and data reporting commence.[3]
• Establish a core clinic team including a programme coordinator, a licensed physician, gynaecologist or obstetrician privileged to provide screening, and a licensed nurse with at least two years’ gynaecology or obstetric nursing experience.[3]
• Provide accredited continuing medical education or continuing professional development, including evidence-based Pap-smear training for physicians.[3]
• Recruit women through targeted facility invitations, opportunistic contact through other screening programmes and physician consultations, and health-promotion campaigns.[2]
• Give culturally and socially relevant information on screening benefits, limitations, outcomes and subsequent care; obtain and document informed consent; and maintain confidential, secure electronic records and data-management systems.[4][6]
• Take menstrual, reproductive, screening, treatment and immunocompromise history, conduct clinical examination including visual cervical inspection, and explain the procedure, possible outcomes and result timeframe.[2]
• Restrict specimen collection to licensed gynaecologists, obstetricians or institutionally privileged physicians, and follow facility procedures for clinical documentation, labelling, storage and transport.[7]
• Avoid collection during menstruation, vaginal inflammation or infection, and pregnancy, except where follow-up of a prior abnormal smear should not be delayed.[7]
• Operate laboratories through documented standard operating procedures for processing, workload, storage, documentation and reporting; maintain internationally recognised accreditation; and participate in external proficiency testing.[6]
• Use the Bethesda System for Reporting Cervical Cytology, require pathologists to verify abnormal and reactive cases, and permit licensed cytotechnologists to verify negative cases using the required synoptic format.[7]
• Notify women in writing, return normal results to routine screening, repeat unsatisfactory tests within 6 to 12 weeks after treating infection where appropriate, and manage abnormal results according to the relevant appendix.[8]
• Refer suspicious visible cervical abnormalities immediately to a gynaecological oncologist, ensure colposcopy is performed by an accredited colposcopist or through referral, and make treatment referrals to appropriately licensed and privileged professionals.[8]
• Schedule urgent follow-up within one to two weeks for high-grade squamous intraepithelial lesion or atypical squamous cells that cannot exclude high-grade lesions, and routine follow-up within two to six weeks for low-grade squamous intraepithelial lesion or atypical squamous cells of undetermined significance.[5]
• Submit screening and outcome data to the National Cancer Screening Registry within three weeks of screening, and notify confirmed screen-detected cancers to the National Cancer Registry using the Cancer Case Notification Form.[4]
• Maintain internal audit processes and evidence of compliance, cooperate with Ministry inspections and authorised audits, and accept independent third-party laboratory quality-assurance testing where directed.[4][7]
• Monitor retention, specimen adequacy, negative-result proportions, cytology turnaround, colposcopy timeliness, biopsy rates, cytology-histology agreement and precancer detection.[9]

Monitoring & Evaluation

The programme establishes a national monitoring and accountability framework covering screening activity, laboratory quality, timeliness of results, referral, follow-up, cancer notification, facility compliance, and external oversight. Participating facilities are required to maintain records and submit screening-visit and outcome data to the National Cancer Screening Registry at the Ministry of Health and Prevention (MOHAP), enabling programme-level tracking of service delivery and follow-up.[4][3][5]

• Submit screening-visit and outcome data to the National Cancer Screening Registry within three weeks of the screening date, through the cancer screening electronic notification system and the facility’s designated programme coordinator.[4][5]
• Report every confirmed screen-detected cancer to the National Cancer Registry at MOHAP using the Cancer Case Notification Form.[4]
• Maintain screening-test and outcome records, electronic patient records, confidentiality and data-security arrangements, and evidence of compliance with clinical quality indicators.[4][6]
• Establish internal audit arrangements and cooperate with MOHAP inspections, audits, and independent third-party laboratory quality-assurance testing.[4][7]
• Monitor specimen adequacy, specimen handling and transport, smear processing and management, laboratory performance, reporting, referral, and completion of follow-up.[4][6][5]

Laboratory and facility reporting timeframes form a principal performance mechanism. Laboratories are to return reports on specimen adequacy and cytological findings to the referring physician within eight working days of receiving the specimen.[7]Screening-facility physicians are to provide women with written results within 15 working days, or three weeks, of specimen collection.[8]The reporting pathologist is responsible for notifying the referring physician of positive cancer results.[7]

Follow-up performance is monitored through referral requirements and defined appointment intervals. Women with suspicious visible cervical abnormalities are to be referred immediately to a gynaecological oncologist, while colposcopy must be delivered by an accredited colposcopist or via referral to an appropriately qualified facility.[8]High-grade squamous intraepithelial lesion and atypical squamous cells where high-grade disease cannot be excluded require urgent appointments within one to two weeks; low-grade squamous intraepithelial lesion and atypical squamous cells of undetermined significance require routine appointments within two to six weeks.[5]Referrals for colposcopy or treatment must be made to suitably licensed and privileged professionals, with attendance within the appendix-defined timeframes.[8]

The guideline specifies quality indicators for retention, specimen adequacy, negative screening results, cytology turnaround time, time to colposcopy, biopsy rates, cytology-histology agreement, and pre-cancer detection.[9]Reported benchmarks distinguish acceptable from desirable performance: retention of 40% and 50%; unsatisfactory specimens of 4.7% and 1.3%; negative screening results of 90% and 97%; cytology turnaround performance above 80% and 90%; and colposcopy within the specified period for 80% and 88% of relevant positive cases.[9]The desirable biopsy rate is 11%, although the acceptable level is not determined in the supplied material, and the desirable pre-cancer detection rate is 7.1 lesions per 1,000 women screened using a Papanicolaou test.[9]

Accountability is assigned at facility, laboratory, and national levels. Facility coordinators recruit eligible women, track results and follow-up, check adherence to approved protocols, address barriers, promote recall and reminder systems, and submit data.[5]Laboratories must operate documented procedures, retain relevant documentation, meet internationally recognised accreditation requirements, and involve personnel in external proficiency testing for Papanicolaou-test screening and reporting.[6]Non-compliance may lead to sanctions imposed by MOHAP under the enforcement provisions.[4]

The bibliography extract cites evidence on cervical cancer incidence, screening disparities, vaccination coverage, and screening uptake, but does not itself add programme-specific monitoring methods, indicators, reporting arrangements, or accountability mechanisms.[10][11][12]

Costing & Financing

No programme budget, unit cost, quantified resource requirement, funding allocation, funding gap, resource-mobilisation target, or economic assumption is specified in the supplied guideline sections.[1][4][2][10][11][12]

• Govern reimbursement eligibility for cervical cancer screening and follow-up through the applicable local health-insurance laws in each Emirate.[4]
• Require service-delivery capacity, including licensed facilities, laboratories, trained staff, equipment, data systems, quality assurance, and referral arrangements, but do not attach explicit financial values to these requirements.[4][6][3]
• Leave unspecified the sources of programme financing, the division of financial responsibilities between national and Emirate-level bodies, and the affordability or cost-effectiveness assumptions underlying screening intervals and testing approaches.[1][4][2]

The bibliography-only extract also contains no explicit cost, budget, financing, or economic-analysis information.[10][11][12]